Taysha Gene Therapies (TSHA) Net Income towards Common Stockholders (2020 - 2026)

Taysha Gene Therapies has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$42.4 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 96.99% year-over-year to -$42.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129.9 million (down 49.69% YoY) and the FY2025 annual result came in at -$109.0 million, down 22.06% from the prior year.
• Net Income towards Common Stockholders declined to -$42.4 million in Q1 2026 per TSHA's latest filing, from -$27.9 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $47.7 million in Q4 2023 and troughed at -$117.1 million in Q3 2023.
• A 5-year average of -$30.5 million and a median of -$26.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 186.68% in 2023, down 341.39% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$55.1 million in 2022, then jumped by 186.68% to $47.7 million in 2023, then plunged by 139.35% to -$18.8 million in 2024, then slumped by 48.26% to -$27.9 million in 2025, then slumped by 52.27% to -$42.4 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$42.4 million, -$27.9 million, and -$32.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.